[ad_1]
Dublin, 31 January 2019 (GLOBE NEWSWIRE) – Drug Pipelines "Idiopathic Pulmonary Fibrosis – Global Manufacturers of APIs, Marketed and Phase III Drugs, 2019" has been added to ResearchAndMarkets.com & # 39; s offer.
Idiopathic Pulmonary Fibrosis – Global Overview of API Manufacturers, Marketed and Phase III Drugs, 2019 "provides comprehensive information on marketed and Phase III products for idiopathic pulmonary fibrosis, including information on marketed products, including their description, details of the 2021 & API manufacturer details by country.
Global APIs for Manufacturers of Marketed Products for Idiopathic Pulmonary Fibrosis
IPA Manufacturers' Coverage for Idiopathic Pulmonary Fibrosis: Products Marketed in the United States, Europe, China and India. Manufacturer details include the manufacturer's name and location.
Emerging phase III products for idiopathic pulmonary fibrosis
This report provides a comprehensive understanding of emerging phase III treatments for idiopathic pulmonary fibrosis, which may be potential future competitors for marketed products. It will also highlight current market trends. Their planned global sales are also provided until 2021.
Scope
- An examination of the products marketed for idiopathic pulmonary fibrosis, including their description, their synthetic route, regulatory milestones, projected sales forecasts until 2021 and the details of the API manufacturers.
- Coverage of patent information of marketed products, including patent number, holder, license and patent expiry
- API manufacturers for marketed products with location details
- New Phase III Product Profiles for Idiopathic Pulmonary Fibrosis, Including Product Description, Development Activities, Licensors and Collaborators and Information on Chemicals
Reasons to buy
- API Intelligence for marketed drugs for indication and understanding of API manufacturers
- Evaluate the marketing status and patent details of products in order to exploit generic drug development opportunities
- Design effective counter-strategies to gain competitive advantage by identifying key details of patent expiration and exclusivity vs. indication
- Establish a global understanding of emerging Phase III products that may be future competitors in this space
Key topics covered:
1. Introduction to the report
2. Idiopathic pulmonary fibrosis: overview
- Risk factors
- The causes
- sYMPTOMS
- pathophysiology
- Prognosis
- Diagnostic
- Treatment
3. Comparative badysis of marketed and emerging products
4. Commercialized therapies
- Product Description
- Synthetic route
- Mechanism of action
- Pharmacology
- pharmacodynamics
- pharmacokinetics
- Side effects
- Clinical tests
- Regulatory milestones
- Product development activities
- product details
- United States
- Europe
- Overall Sales Assessment
- Historical global sales
- Forecast global sales
- Details of the patent
5. Emerging therapies (phase III)
- Product Description
- Research and development
- Product development activities
- Forecast global sales
For more information on this report on drug pipelines, visit https://www.researchandmarkets.com/research/32tkq5/global_idiopathic?w=12.
Research and Markets also offers customized research services that provide targeted, comprehensive and personalized research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Secretary [email protected] For office hours, call 1-917-300-0470 For toll-free calls to the United States and Canada: 1-800-526-8630 For GMT office hours, call + 353-1-416-8900 Related Themes: Respiratory Drugs
Source link
